BCL2 and breast cancer: Structural optimization derivatives, including Bis-demethoxycurcumin (BDMC) for breast and gastric cancers [203,204], Tetrahydrocurcumin (THC) for BC [205], and Demethoxycurcumin (DMC) for lung cancer [193], can mediate alterations in mitochondrial outer membrane permeability by upregulating the Bax/Bcl-2 ratio and enhancing ROS accumulation.